Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TGM 407

Next Previous
Drug Profile

TGM 407

Alternative Names: ETX-407; TGM-407

Latest Information Update: 06 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator e-Therapeutics
  • Developer Tangram Therapeutics
  • Class Amides; Amino sugars; Drug conjugates; Eye disorder therapies; Small interfering RNA
  • Mechanism of Action Protein expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Dry age-related macular degeneration

Most Recent Events

  • 06 Nov 2025 Adverse events and pharmacodynamics data from preclinical trials in Dry age-related macular degeneration released by Tangram Therapeutics (Tangram Therapeutics pipeline, November 2025)
  • 01 Oct 2025 e-Therapeutics is now called Tangram Therapeutics
  • 27 Oct 2023 Preclinical trials in Dry age related macular degeneration in United Kingdom (SC), before October 2023 (e-Therapeutics pipeline, October 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top